| Literature DB >> 31446161 |
Zhong-Zhou Huang1, Ying Xu2, Min Xu1, Zhen-Rui Shi1, Shao-Zhen Mai3, Zhi-Xuan Guo1, Zeng-Qi Tang1, Yi-Jin Luo1, Qing Guo4, Hui Xiong5.
Abstract
Artesunate (ART), a derivative of artemisinin, is a medication to treat malaria. Beyond that, the anti-inflammatory and immunoregulatory activities of ART have been identified in autoimmune diseases. However, whether ART functions in psoriasis-like dermatitis induced by imiquimod (IMQ, a TLR7/8 agonist) is currently unkown. There, we found that the cumulative score, epidermal thickening and expression of Ki-67 of ART-treated BALB/c mice were significantly lower than those in the IMQ psoriatic model group. In addition, ART treatment ameliorated mice from systemic inflammation. Mechanistically, ART reduced γδ T cells in draining lymph nodes, which might be benefit the improvement of dermatitis. These findings suggested that ART could be a promising drug of psoriasis in clinic.Entities:
Keywords: Artesunate; Dermatitis; Imiquimod; Psoriasis; γδ T cells
Mesh:
Substances:
Year: 2019 PMID: 31446161 DOI: 10.1016/j.intimp.2019.105817
Source DB: PubMed Journal: Int Immunopharmacol ISSN: 1567-5769 Impact factor: 4.932